BRAF and autoimmune disease: Interestingly, our repositioning approach showed that the B-RAF inhibitors Sorafenib, Regorafenib and Dabrafenib and the JAK1/2 inhibitor Baricitinib, which are commonly used to treat cancer and autoimmune diseases [67,68], led to a significant increase in virus infection.